Literature DB >> 22453196

Sildenafil increases digital skin blood flow during all phases of local cooling in primary Raynaud's phenomenon.

M Roustit1, M Hellmann, C Cracowski, S Blaise, J L Cracowski.   

Abstract

Digital skin vasoconstriction on local cooling is exaggerated in primary Raynaud's phenomenon (RP) as compared with controls. A significant part of such vasoconstriction relies on the inhibition of the nitric oxide (NO) pathway. We tested the effect of the phosphodiesterase 5 (PDE5) inhibitor sildenafil, which potentiates the effect of NO, on skin blood flow. We recruited 15 patients with primary RP, performing local cooling without sildenafil (day 1), after a single oral dose of 50 mg (day 2), and after a dose of 100 mg (day 3). Skin blood flow, skin temperature, and arterial pressure were recorded, and data were expressed as cutaneous vascular conductance (CVC). Sildenafil at 100 mg, but not 50 mg, significantly lessened the cooling-induced decrease in CVC. It also increased resting CVC and skin temperature. These data suggest that 100 mg sildenafil improves digital skin perfusion during local cooling in primary RP. The benefit of sildenafil "as required" should be confirmed in a randomized, controlled trial.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22453196      PMCID: PMC4000564          DOI: 10.1038/clpt.2011.302

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  31 in total

1.  Gender differences in cutaneous laser doppler flow response to local direct and contralateral cooling.

Authors:  K Cankar; Z Finderle; M Strucl
Journal:  J Vasc Res       Date:  2000 May-Jun       Impact factor: 1.934

2.  Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease.

Authors:  Philip B Furspan; Soumya Chatterjee; Robert R Freedman
Journal:  Arthritis Rheum       Date:  2004-05

Review 3.  Raynaud's phenomenon and the role of capillaroscopy.

Authors:  Maurizio Cutolo; Walter Grassi; Marco Matucci Cerinic
Journal:  Arthritis Rheum       Date:  2003-11

4.  Regional vascular resistance vs. conductance: which index for baroreflex responses?

Authors:  D S O'Leary
Journal:  Am J Physiol       Date:  1991-02

5.  Impaired transient vasodilation and increased vasoconstriction to digital local cooling in primary Raynaud's phenomenon.

Authors:  Matthieu Roustit; Sophie Blaise; Claire Millet; Jean-Luc Cracowski
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-05-13       Impact factor: 4.733

6.  Diagnosis of Raynaud's phenomenon assisted by color charts.

Authors:  H R Maricq; M C Weinrich
Journal:  J Rheumatol       Date:  1988-03       Impact factor: 4.666

7.  Nitric oxide and neurally mediated regulation of skin blood flow during local heating.

Authors:  C T Minson; L T Berry; M J Joyner
Journal:  J Appl Physiol (1985)       Date:  2001-10

Review 8.  Raynaud's phenomenon: a proposal for classification.

Authors:  E C LeRoy; T A Medsger
Journal:  Clin Exp Rheumatol       Date:  1992 Sep-Oct       Impact factor: 4.473

9.  Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.

Authors:  Peter A Merkel; Karen Herlyn; Richard W Martin; Jennifer J Anderson; Maureen D Mayes; Patrice Bell; Joseph H Korn; Robert W Simms; Mary Ellen Csuka; Thomas A Medsger; Naomi F Rothfield; Michael H Ellman; David H Collier; Arthur Weinstein; Daniel E Furst; Sergio A Jiménez; Barbara White; James R Seibold; Fredrick M Wigley
Journal:  Arthritis Rheum       Date:  2002-09

10.  Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon.

Authors:  C B Bunker; G Terenghi; D R Springall; J M Polak; P M Dowd
Journal:  Lancet       Date:  1990 Dec 22-29       Impact factor: 79.321

View more
  7 in total

1.  Effects of phosphodiesterase type 5 inhibitors on Raynaud's phenomenon.

Authors:  Yasuyuki Kamata; Seiji Minota
Journal:  Rheumatol Int       Date:  2014-05-01       Impact factor: 2.631

Review 2.  Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension.

Authors:  Steven G Chrysant
Journal:  Curr Hypertens Rep       Date:  2013-10       Impact factor: 5.369

Review 3.  Strategies to increase nitric oxide signalling in cardiovascular disease.

Authors:  Jon O Lundberg; Mark T Gladwin; Eddie Weitzberg
Journal:  Nat Rev Drug Discov       Date:  2015-08-07       Impact factor: 84.694

Review 4.  The role of phosphodiesterase-5 inhibitors in prostatic inflammation: a review.

Authors:  Christina Alves Peixoto; Fabiana Oliveira Dos Santos Gomes
Journal:  J Inflamm (Lond)       Date:  2015-09-15       Impact factor: 4.981

5.  PDE5 Exists in Human Neurons and is a Viable Therapeutic Target for Neurologic Disease.

Authors:  Andrew F Teich; Mikako Sakurai; Mitesh Patel; Cameron Holman; Faisal Saeed; Jole Fiorito; Ottavio Arancio
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

6.  Innovations in the Assessment of Primary and Secondary Raynaud's Phenomenon.

Authors:  Barbara Ruaro; Vanessa Smith; Alberto Sulli; Carmen Pizzorni; Samuele Tardito; Massimo Patané; Sabrina Paolino; Maurizio Cutolo
Journal:  Front Pharmacol       Date:  2019-04-16       Impact factor: 5.810

7.  Influence of 8-Week Aerobic Training on the Skin Microcirculation in Patients with Ischaemic Heart Disease.

Authors:  Renata Szyguła; Monika Wierzbicka; Grażyna Sondel
Journal:  J Aging Res       Date:  2020-01-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.